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Regression analysis of mortality data from the EPHESUS trial
reveals significantly higher risk of death for patients with non-ST
segment elevation myocardial infarction
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Purpose: The EPHESUS trial demonstrated that aldosterone blockade
with eplerenone significantly decreased risk of all-cause mortality and
cardiovascular (CV) death in post-acute MI patients with heart failure
(HF) by 15% (P = 0.008) and 17% (P = 0.005), respectively. This post
hoc analysis of the EPHESUS trial explored trends in mortality data by
baseline ST segment elevation status (STEMI vs. NSTEMI).
Methods: 6632 patients with signs and symptoms of CHF post AMI
with LVSD (EF < 40%) were randomized to receive either eplerenone
or placebo in addition to standard therapy. In this subanalysis, subjects
were stratified based on STEMI status at baseline. Statistical analyses
were performed using Cox regression with treatment and STEMI status
as variables.
Results: 74% and 71% of patients in the eplerenone and placebo groups,
respectively, were identified as having STEMI at baseline (Table). Mean
age at baseline was 63±11.1 y for subjects with STEMI and 67±11.5
y for subjects with NSTEMI. All cause mortality was significantly
higher in patients with NSTEMI (19.8%) than in those with STEMI
(13.5%). A similar trend was observed for other endpoints such as CV
deaths/hospitalizations. Results of the full Cox model, with baseline char-
Table 1. Summary of cause of death and analyses
Status N All-cause deaths, CV deaths/hospitalization, CV deaths,
n (%) n (%) n (%)
NSTEMI Placebo 946 199 (21.0) 333 (35.2) 168 (17.8)
Eplerenone 861 158 (18.4) 274 (31.8) 137 (15.9)
STEMI Placebo 2304 342 (14.8) 631 (27.4) 303 (13.2)
Eplerenone 2399 295 (12.3) 580 (24.2) 250 (10.4)
Cox Proportional Hazards Model (all-cause death)
Covariate Hazard Ratio 95% CI P-value
Treatment (Eplerenone: Placebo) 0.826 (0.729, 0.936) 0.003
Q-Wave (Yes: No) 0.672 (0.590, 0.765) <0.001
acteristics as covariates, indicated that higher risk of deaths in NSTEMI
patients may be due to imbalanced baseline age, time-to-AMI random-
ization, diagnosis of diabetes, and reperfusion status. Additionally, the
benefit of eplerenone over placebo was similar among patients with either
STEMI or NSTEMI.
Conclusion: In the EPHESUS trial the risk of death was significantly
higher for patients with NSTEMI. However, the benefit of eplerenone
was independent of STEMI status
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Intra-thoracic impedance fluid index alerts are associated with
increased risk for heart failure hospitalization
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Introduction: Modern implantable defibrillators allow the long-
term monitoring of several diagnostic indices, including intrathoracic
impedance. We determined the association between these indices and
heart failure (HF) hospitalization.
Methods: Both clinical and device diagnostic data, including intratho-
racic impedance, were collected from 558 HF patients indicated for CRT-
D from 34 centers encompassing 326±216 days of follow-up. Device-
recorded thoracic impedance fluid index, mean activity counts, night
heart rate (NHR) and heart rate variability (HRV) were studied.
Results: Patients hospitalized for HF (n=39) had significantly higher
rate of impedance index threshold crossing events (TCE) and higher
percentage of days with the impedance index above the programmed
threshold. Patient groups with low activity, low HRV or high NHR, were
all significantly more likely to be hospitalized for HF (Table 1).
Multivariate analysis showed that each TCE resulted in a 36% increased
Table 1
Hospitalized Patients Patients not Hospitalized p*
Median (25-75%) Median (25-75%)
TCE (yr-1) 2.99 (1.41, 3.82) 1.41 (0.51, 2.55) <0.001
TCE Burden (day ·yr-1) 61.93 (24.43, 94.45) 18.88 (1.65, 43.68) <0.001
Low Acitivity Days (yr-1) 20.56 (6.40, 59.91) 3.74 (1.41, 17.69) <0.001
Low HRV days (yr-1) 77.52 (6.71, 130.13) 12.06 (0.65, 88.99) 0.016
High NHR Days (yr-1) 19.06 (1.59, 66.82) 1.86 (0.00, 22.28) 0.003
